Overview
- The FDA, following calls from Health Secretary Robert F. Kennedy Jr. to relax limits, plans an advisory review this summer on whether compounding pharmacies can make certain experimental peptides.
- The review will include BPC‑157, a widely promoted compound tied to tissue healing in animals but lacking rigorous human trials.
- Doctors and the FDA warn of specific risks with these products, including immune reactions, signals that could spur some cancers, contamination and inconsistent dosing.
- Analysts say looser rules could boost telehealth firms, compounding pharmacies and longevity clinics, with Hims & Hers shares recently jumping as investors bet on new peptide sales.
- Many people already buy “research‑use‑only” vials from overseas and inject themselves, exposing gaps in purity, labeling and dosing, while few trained clinicians and unclear pharmacy rules leave limited trusted guidance.